← Leaderboards
John Francis Hines
Yale University
$611,910
Attributed
$611,910
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $122.4K · FY2016–20$200K$150K$100K$50K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$611,910 · 1
By mechanism
R50$611,910 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Seth B. Herzon$10,471,068
- Craig M Crews$33,790,660
- Diane McMahon Pratt$11,622,683
- Anthony J Koleske$16,724,381
- Walther H Mothes$28,899,611
Others in their field
Top investigators on “Xenograft Model”
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- David Heimbrook · Leidos Biomedical Research, Inc.$97,842,001
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Samuel Singer · Sloan-Kettering Inst Can Research$23,058,247
- Larry Arthur$20,604,376
Research focus
Xenograft ModelAmericasSignal TransductionSmall MoleculeSmall Molecule InhibitorStomachTranscriptomeTumorUbiquitinationAnti-Cancer TherapeuticBiologyBreastCancer CellCancer TherapyColorectalCytoplasmic TailDesignDrug CandidateFightingLigandsLinkLungMalignant NeoplasmsMedicine
Grant awards (5)
Investigating targeted degradation of c-Met to realize more effective cancer treatment$122,382
R50 · FY2020 · CA · contact PI
Investigating targeted degradation of c-Met to realize more effective cancer treatment$122,382
R50 · FY2019 · CA · contact PI
Investigating targeted degradation of c-Met to realize more effective cancer treatment$122,382
R50 · FY2018 · CA · contact PI
Investigating targeted degradation of c-Met to realize more effective cancer treatment$122,382
R50 · FY2017 · CA · contact PI
Investigating targeted degradation of c-Met to realize more effective cancer treatment$122,382
R50 · FY2016 · CA · contact PI